OrphoMed: OrphoMed's ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
(marketscreener.com) -- Topline data anticipated second half of 2021-- https://www.marketscreener.com/news/latest/OrphoMed-s-ORP-101-Passes-Second-Planned-Interim-Analysis-in-Phase-2-Study-of-Treatment-for-IBS-D-Pa--32965971/?utm_medium=RSS&utm_content=20210414
Read full article »
OrphoMed is a biopharmaceutical company that develops dimer therapies for visceral hypersensitivity and hypermotility in gastrointestinal disorders.
Read more